10:30 - 12:30
| | Parallel Session 14:
Innovative Therapeutic Approaches | | Auditorium |
| | Moderators: | John E. Tavis | St. Louis |
| | | Alexander J. Thompson | Melbourne |
10:30 | SP-079 | Therapeutic Advances for the Management of HDV | Michael P. Manns | Hannover |
10:50
| SP-080 | Aggregate Report on Safety and Efficacy of a New Sustained Release IFN (IFN XL) as Compared to Standard of Care | Christian Trépo
| Lyon
|
11:10 | SP-081 | IFN-Free Strategies for HCV | Edward J. Gane | Auckland |
11:30
| SP-082
| Myrcludex B, A Novel Entry Inhibitor for Hepatitis B and Hepatitis Delta Virus (HDV) Infections | Stephan Urban
| Heidelberg
|
11:50
| OP-032
| Identification of the Disubstituted Sulfonamide Compounds as Specific Inhibitors of HBV cccDNA Formation | Hai-Tao Guo
| Doylestown
|
12:05
| OP-033
| Restoration of Immune Function and Control of chronic HBV Infection after Clearance of Serum HBsAg by Nucleic Acid Polymers. | Andrew Vaillant
| Montreal
|